Published in J Virol on August 01, 1990
Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci U S A (1992) 1.60
Antigenicity of rabies virus glycoprotein. J Virol (1991) 1.50
Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product. J Virol (1993) 1.23
Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc Natl Acad Sci U S A (1997) 1.23
Immunization against rabies with plant-derived antigen. Proc Natl Acad Sci U S A (1998) 1.21
First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs. J Virol (1994) 1.17
Virus neutralization by germ-line vs. hypermutated antibodies. Proc Natl Acad Sci U S A (2000) 1.16
Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13
An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain. J Virol (1993) 1.13
Molecular and cellular aspects of rhabdovirus entry. Viruses (2012) 1.12
Chimeric lyssavirus glycoproteins with increased immunological potential. J Virol (1999) 0.97
Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans. FASEB J (2013) 0.87
Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine. PLoS One (2011) 0.84
Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Ther Adv Vaccines (2015) 0.81
Re-emergence of rabies in the Guangxi province of Southern China. PLoS Negl Trop Dis (2014) 0.81
Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins. PLoS One (2013) 0.81
Characterization and potential diagnostic application of monoclonal antibodies specific to rabies virus. J Biomed Res (2010) 0.80
A novel double-antigen sandwich enzyme-linked immunosorbent assay for Measurement of Antibodies against rabies virus. Clin Vaccine Immunol (2006) 0.79
Mutations conferring resistance to neutralization by a soluble form of the neurotrophin receptor (p75NTR) map outside of the known antigenic sites of the rabies virus glycoprotein. J Virol (2002) 0.78
Benchmarking B-cell epitope prediction with quantitative dose-response data on antipeptide antibodies: towards novel pharmaceutical product development. Biomed Res Int (2014) 0.76
Sequencing and molecular characterization of CTNCEC25, a China fixed rabies virus vaccine strain CTN-1 adapted to primary chicken embryo cells. Virol J (2014) 0.75
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem (1987) 59.79
Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol (1978) 29.77
Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein. J Virol (1985) 3.06
Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A (1984) 2.85
Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev Biol Stand (1984) 2.20
Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun (1977) 2.14
Induction and biological properties of defective interfering particles of rabies virus. J Virol (1977) 2.02
Effective protection of monkeys against death from street virus by post-exposure administration of tissue-culture rabies vaccine. Bull World Health Organ (1971) 1.85
Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J Virol (1988) 1.62
Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. J Gen Virol (1983) 1.50
Antigenic structure of rabies virus glycoprotein: ordering and immunological characterization of the large CNBr cleavage fragments. J Virol (1982) 1.45
Localization and immunological characterization of antigenic domains of the rabies virus internal N and NS proteins. Virus Res (1987) 1.42
Induction of rabies virus-specific T-helper cells by synthetic peptides that carry dominant T-helper cell epitopes of the viral ribonucleoprotein. J Virol (1989) 1.27
Isolation and purification of a polymeric form of the glycoprotein of rabies virus. J Gen Virol (1978) 1.26
Antigenic variants of CVS rabies virus with altered glycosylation sites. Virology (1985) 1.20
Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. J Gen Virol (1989) 1.15
Investigation of the antigenic structure of rabies virus glycoprotein by monoclonal antibodies. Dev Biol Stand (1984) 1.08
Chromatographic separation according to size of macromolecules and cell particles on columns of agarose suspensions. Arch Biochem Biophys (1962) 1.04
Engineering of immunogenic peptides by co-linear synthesis of determinants recognized by B and T cells. Eur J Immunol (1987) 1.03
T cell responses to cleaved rabies virus glycoprotein and to synthetic peptides. J Immunol (1984) 0.98
Preparation and characterization of rabies virus hemagglutinin. Infect Immun (1980) 0.80
A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med (2001) 16.32
Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet (1998) 16.30
Emerging marine diseases--climate links and anthropogenic factors. Science (1999) 10.22
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
A pandemic warning? Nature (1997) 8.70
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill (2012) 7.96
Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet (1979) 7.28
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol (2000) 6.96
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23
Activation of production of infectious tumor virus SV40 in heterokaryon cultures. Proc Natl Acad Sci U S A (1967) 6.05
Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol (1995) 5.67
A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science (1991) 5.60
An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science (1994) 5.10
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03
Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill (2012) 4.95
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol (2001) 4.90
MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity (1994) 4.65
Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc Natl Acad Sci U S A (1983) 4.54
Chromosomal location of the genes for human immunoglobulin heavy chains. Proc Natl Acad Sci U S A (1979) 4.52
Production of antibodies against influenza virus by somatic cell hybrids between mouse myeloma and primed spleen cells. Proc Natl Acad Sci U S A (1977) 4.30
Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci U S A (1978) 4.24
Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature (1995) 4.18
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell (1995) 4.13
A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem (1982) 3.97
Specific antigen in serum of patients with colon carcinoma. Science (1981) 3.68
Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods (1998) 3.67
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A (1979) 3.46
Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature (1984) 3.32
Comparison of the ribonucleic acid polymerases of two rhabdoviruses, Kern Canyon virus and vesicular stomatitis virus. J Virol (1971) 3.26
Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem (1995) 3.17
Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res (1983) 3.15
Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. Proc Natl Acad Sci U S A (1978) 3.03
Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill (2013) 2.97
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol (1997) 2.86
Replication-defective vector based on a chimpanzee adenovirus. J Virol (2001) 2.86
Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A (1984) 2.85
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature (1999) 2.80
Antigenic properties of rabies virus components. J Immunol (1973) 2.68
Purification of rabies virus grown in tissue culture. J Virol (1968) 2.67
Effect of polyions on the infectivity of rabies virus in tissue culture: construction of a single-cycle growth curve. J Virol (1967) 2.67
New assay procedure for separation of mycoplasmas from virus pools and tissue culture systems. J Virol (1967) 2.64
Assignment of the T-antigen gene of simian virus 40 to human chromosome C-7. Proc Natl Acad Sci U S A (1973) 2.63
Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity (1995) 2.63
Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders. Science (1985) 2.57
A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet (1999) 2.56
Isolation of latent herpes simplex virus from the superior cervical and vagus ganglions of human beings. N Engl J Med (1978) 2.55
The effect of feeding with a tryptophan-free amino acid mixture on rat-liver polysomes and ribosomal ribonucleic acid. Biochem J (1966) 2.53
Antigenic variants of rabies virus. J Exp Med (1980) 2.51
Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA (1976) 2.47
Herpes simplex type 1 DNA in human brain tissue. Proc Natl Acad Sci U S A (1981) 2.45
Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther (1996) 2.43
Structural proteins of rabies virus. J Virol (1971) 2.42
Effect of environmental pH on the efficiency of cellular hybridization. Proc Natl Acad Sci U S A (1972) 2.39
Repertoire of antiviral antibodies expressed by somatic cell hybrids. Proc Natl Acad Sci U S A (1978) 2.38
A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology (1996) 2.35
Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A (1995) 2.33
Production of human hybridomas secreting antibodies to measles virus. Nature (1980) 2.32
Immune lysis of rabies virus-infected cells. J Immunol (1968) 2.25
Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet (1982) 2.25
Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol (2000) 2.25
Influenza virus hemagglutinin-specific antibodies isolated from a combinatorial expression library are closely related to the immune response of the donor. Proc Natl Acad Sci U S A (1990) 2.24
Amplification and molecular cloning of HTLV-I sequences from DNA of multiple sclerosis patients. Science (1989) 2.23
Molecular recognition and the future of monoclonal antibodies. Nature (1982) 2.22
Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A (1998) 2.21
Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies. Clin Diagn Lab Immunol (2000) 2.21
Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res (1982) 2.21
Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev Biol Stand (1984) 2.20
Presence of 2 different viral agents in brain cells of patients with subacute sclerosing panencephalitis. Proc Soc Exp Biol Med (1970) 2.20
Virus replication in enucleate cells: vesicular stomatitis virus and influenza virus. J Virol (1974) 2.19
Early events in the infection of permissive cells with simian virus 40: adsorption, penetration, and uncoating. J Virol (1970) 2.18
Human influenza virus A/HongKong/156/97 (H5N1) infection. Vaccine (1998) 2.17
Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol (1998) 2.15
IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci U S A (1982) 2.15
Morphology of the nucleoprotein component of rabies virus. J Virol (1968) 2.13
Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U S A (1983) 2.12
Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol (2000) 2.11
Respiratory syncytial virus proteins. Virology (1976) 2.11
Haemorrhagic fever with renal syndrome. Lancet (1993) 2.09
Structure of the glycoprotein gene in rabies virus. Nature (1981) 2.09
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol (1997) 2.07
Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol (2000) 2.07
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
Canine distemper virus from diseased large felids: biological properties and phylogenetic relationships. J Gen Virol (1996) 2.06
An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol (1999) 2.06
Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. J Virol (1999) 2.04
Laboratory techniques in rabies. Mouse inoculation test. Monogr Ser World Health Organ (1966) 2.04
Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology (1994) 2.04
Induction and biological properties of defective interfering particles of rabies virus. J Virol (1977) 2.02
Virus particles in early mouse embryos. J Natl Cancer Inst (1973) 2.02
A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science (1981) 2.02
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med (1999) 2.01
Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo and in vitro. J Virol (1985) 2.00